Navigation Links
Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial

SKILLMAN, N.J., Sept. 28, 2011 /PRNewswire/ -- Findings from an international Phase 3 clinical trial of the Vitala™ Continence Control Device (CCD) showed the device was safe and effective at restoring continence when worn up to 12 hours per day by people with a colostomy.  In addition, 87% of users rated the ability of the device to restore continence as "good" or "very good," according to the study results published in the British Journal of Nursing.(1)

Developed by ConvaTec, Vitala™ CCD is an innovative, non-invasive device that allows individuals to manage their colostomy without having to wear a pouch or incorporate irrigation. When in use, Vitala™ CCD prevents the uncontrolled release of stool, which is stored inside the body, while permitting gas to vent through an integrated, deodorizing filter.  The unique design also helps reduce noise and odors, and the discreet low profile device helps make the presence of an ostomy less noticeable.(1)

"For people with a colostomy, the loss of continence control gives rise to multiple concerns that can negatively impact their quality of life," said lead study investigator Ann Durnal, RN, BSN, CWOCN. "These findings, which are consistent with those of an earlier Phase 2 study, indicate that this transformational technology can achieve the goal of colostomy continence that has for so long eluded us."

The Phase 3 clinical study, conducted at 16 centers in the U.S. and Europe, evaluated the safety and efficacy of the device when worn up to 12 hours by individuals with an end colostomy for nearly six months.  Participants in the study (n=78) were monitored across a range of treatment stages, including usual pouching (21 days), skin barrier transition (14 days), and device wear (21 days of device ramp-up increasing to 12 hours of daily wear for 159 days).

After the study period of 215 days, results showed that there were no serious adverse events related to wearing the device. No changes to stoma vascularity or gut microbiology were observed throughout the device wear stage.(1)

The majority of participants in the study found Vitala™ CCD easy to apply (76%), remove (99%) and dispose of (100%). More than four out of five users (83%) reported less odor than their usual device and three out of five (60%) said they experienced no noise while wearing Vitala™ CCD. The device was also reported to be comfortable by 94% of participants and its profile acceptable by 77% of participants.   At the end of the study period, approximately 70% of participants, who had used traditional pouching systems on average for more than six years, stated that they preferred Vitala™ CCD to their usual pouching system.(1)

"Vitala™ CCD was developed to give people with a colostomy regained control, more confidence and greater freedom, allowing them to feel much like they did before surgery," said Dheerendra Kommala, MD, Chief Medical Officer, ConvaTec. "In developing this novel technology, it was important to offer a high level of control with a device that is comfortable, safe, and able to manage noise and odor. The results of this clinical study provide further evidence that Vitala™ CCD truly represents a new era in ostomy care."

Vitala™ is currently available in the Czech Republic, Netherlands and the United Kingdom with additional introductions scheduled for Austria and Denmark.  Vitala™ CCD is recommended for use a minimum of six weeks after surgery.  Full product use information is available in the package insert.  For more information about Vitala™ CCD, please contact the ConvaTec customer information center.

About ConvaTecConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit is a trademark of ConvaTec Inc. © 2011 ConvaTec Inc.SC-000258-MM(1) Durnal, A., Maxwell, T., Kiran, R.P. & Kommala, D. (2011) International study of a continence device with 12-hour wear times. British Journal of Nursing, 20(16), S28-S36.


Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ConvaTec Presents New Data on ConvaTec Moldable Technology™ and Vitala™ Continence Control Device in Ostomy Care
2. Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee
3. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
4. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
5. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
6. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
7. Zassi Medical Evolutions Spins out Electrical Stimulation Technology for Gastrointestinal Continence Control and Forms New Company with Technology Investment Firm
8. NanoPowers Raises CHF 5 Million ($4.5 Million) in Series A Financing to Support Development of Breakthrough Urinary Incontinence Device
9. Boston Scientifics Womens Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association
10. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
11. FDA Approves Injectable Gel to Treat Fecal Incontinence
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Breg, ... and services, announced today that it has been awarded ... organization. Members served by Novation will have access to ... sports bracing products and soft goods dedicated to advancing ... --> The aging U.S. population, rising prevalence of ...
(Date:12/1/2015)... , Dec. 1, 2015 Building on ... Johnson & Johnson (NYSE: JNJ ) today ... Pharmaceutical Companies to significantly reduce the burden of ... up 74 percent of new HIV infections among ... World AIDS Day, these new initiatives include collaborations ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Growth in medical payments per workers’ compensation claim in ... hospital and nonhospital care, according to a recent study by the Workers Compensation Research ... , found medical payments per claim with more than seven days of lost time ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
Breaking Medicine News(10 mins):